Eli Lilly and Company (NYSE:LLY) Trading 0.1% Higher After Analyst Upgrade
Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price rose 0.1% on Tuesday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist Financial ...
Eli Lilly’s Results Already Disappointed the Street. More Details Come Thursday.
The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.
Truist maintains Eli Lilly stock Buy rating, $1038 target
Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...
FiercePharma13h
TV drug ad spending reached new heights in January, as Novartis' Pluvicto toppled AbbVie's Skyrizi for top spot
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
How Eli Lilly is approaching GLP-1 marketing and what’s next
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...